Once incumbents sell the pill, the oral premium drains out of clinical-stage challengers.
As Lilly and Novo scale approved oral scripts at $149 starter pricing, the oral optionality embedded in pre-revenue developers compresses — Structure Therapeutics ground to a 52-week low on zero corporate news while Viking slipped 32% below its high awaiting its own Phase 3.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Structure's 73% drawdown at RSI 1 with no company-specific event is a repricing of oral optionality against incumbents already selling approved pills.
Viking trades 32% below its 52-week high because its registrational oral program is still pending while incumbent orals capture the market's attention and volume.